15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Syndax Pharmaceuticals Inc, 11 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $34.00 to $57.00, a moderate spread. The average target of $42.45 sits 107% above the current $20.54. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-0.36 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy11100%
Hold00%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Syndax Pharmaceuticals Inc.
As of Jul, 11 of 11 firms rate SNDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SNDX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.59 – $-0.21 · 11 analysts · -48% YoY
Next period, 11 analysts expect Syndax Pharmaceuticals Inc to earn $-0.36 a share (range $-0.59 – $-0.21), versus $-0.70 a year earlier. Full-year consensus is $-1.60, growing to $-0.36 the year after.
REVENUE · NEXT QUARTER
$92.3M
Range $78.1M – $101.8M · 11 analysts · +101% YoY
Revenue is expected to reach $92.3M (range $78.1M – $101.8M), +101.1% year-over-year. Full-year consensus is $344.8M, rising to $503.9M next year.
Top analysts covering Syndax Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SNDX.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$32.00+55.8% to target
Overall win rate
55%
+ Follow
#2
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$33.00+60.7% to target
Overall win rate
53%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #62
Buy
$45.00+119.1% to target
Overall win rate
46%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$57.00+177.6% to target
Overall win rate
43%
+ Follow
#5
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$40.00+94.8% to target
Overall win rate
38%
+ Follow
SNDX stock forecast FAQ
What is SNDX's average 12-month price target?+
The 11 analysts with a live target average $42.45 for Syndax Pharmaceuticals Inc over the next 12 months, ranging from a $57.00 high to a $34.00 low.
Is SNDX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 11 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SNDX?+
The Street-high target is $57.00 (Citigroup), and the Street-low is $34.00 (Goldman Sachs). The average of all 11 active targets is $42.45.
How many Wall Street analysts cover SNDX?+
11 analysts have an active rating on Syndax Pharmaceuticals Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering SNDX?+
Among analysts who currently cover SNDX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $32.00 target.
What is Syndax Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.59 – $-0.21) across 11 analysts. Full-year EPS is projected at $-1.60, rising to $-0.36 the following year.
How much revenue is Syndax Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $92.3M (range $78.1M – $101.8M). Full-year revenue is projected at $344.8M, growing to $503.9M next year.
Have analysts been upgrading or downgrading SNDX lately?+
As of Jul, 11 of 11 firms rate SNDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SNDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
